15:30 Chairperson’s Opening
Christopher Ballas, Senior Vice President of Manufacturing, Innovative Cellular Therapeutics

15:35 Introducing the CoupledCAR Platform for Solid Tumor Therapy

• Development of an indirect CAR approach
• Experience with a multi-vector product
• Early clinical experience

Christopher Ballas, Senior Vice President of Manufacturing, Innovative Cellular Therapeutics

15:50 Engineering Gamma Delta TCR for an Innovative Tumor Specific Cell Therapy

Mark Throsby, Chief Scientific Officer, Gadeta

16:05 Targeting Oncogenic Driver Mutations with TCR Therapies in Solid Tumors

• Selection of TCRs to target oncogenic driver mutations
• Engineering TCR therapies with immune modulatory fusion proteins (IFPs) and switches to overcome the tumor microenvironment
• Gene editing approaches to optimize TCR therapies in solid tumors

Jak Knowles, Chief Executive Officer, Affini-T Therapeutics

16:20 Technical Solutions: Cell Therapies for Solid Tumors

• Adapting known manufacturing paradigms to solid tumor-targeted therapeutics
• Gene editing approaches for efficient tumor targeting
• Moving with the industry, dynamics of technology development to meet market need

Nina Bauer, Director, Head of Commercial, Gene Editing and Novel Modalities, MilliporeSigma

16:35 Speaker Q&A and Panel Discussion